Authors: Hanifin, JM Thurston, M Omoto, M Cherill, R Tofte, SJ Graeber, M

Citation: Jm. Hanifin et al., The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis, EXP DERMATO, 10(1), 2001, pp. 11-18

Authors: Luger, T Van Leent, EJM Graeber, M Hedgecock, S Thurston, M Kandra, A Berth-Jones, J Bjerke, J Christophers, E Knop, J Knulst, AC Morren, M Morris, A Reitamo, S Roed-Petersen, J Schoepf, E Thestrup-Pedersen, K Van der Valk, PGM Bos, JD

Citation: T. Luger et al., SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis, BR J DERM, 144(4), 2001, pp. 788-794

Authors: Paul, C Graeber, M Stuetz, A

Citation: C. Paul et al., Ascomycins: promising agents for the treatment of inflammatory skin diseases, EXPERT OP I, 9(1), 2000, pp. 69-77

Authors: Queille-Roussel, C Graeber, M Thurston, M Lachapelle, JM Decroix, J de Cuyper, C Ortonne, JP

Citation: C. Queille-roussel et al., SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge, CONTACT DER, 42(6), 2000, pp. 349-350

Authors: Merkel, T Graeber, M Pagel, L

Citation: T. Merkel et al., A new technology for fluidic microsystems based on PCB technology, SENS ACTU-A, 77(2), 1999, pp. 98-105

Authors: Mrowietz, U Graeber, M Brautigam, M Thurston, M Wagenaar, A Weidinger, G Christophers, E

Citation: U. Mrowietz et al., The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis whenused topically under occlusion, BR J DERM, 139(6), 1998, pp. 992-996